Labetalol S.A.L.F. (Labetalol Hydrochloride)

Labetalol blocks alpha‑1 adrenergic receptors, causing vasodilation and reduced peripheral resistance, while also antagonizing beta‑1 and beta‑2 receptors, decreasing heart rate and cardiac output. The combined effect results in a prompt and controlled reduction of systemic blood pressure.

The dose of labetalol is individualized and determined by the prescribing clinician based on the severity of hypertension, patient weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate infusion rate and total dose.

Labetalol is classified as a pregnancy category with limited data, but it is commonly used under specialist supervision for severe hypertension and preeclampsia because its benefits may outweigh potential risks. Use during breastfeeding is not well studied; clinicians should weigh maternal benefits against possible infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative, sodium nitroprusside, provides rapid vasodilation but can cause cyanide toxicity with prolonged use. Labetalol offers combined alpha‑ and beta‑blockade, reducing both vascular resistance and cardiac output, and generally has a more favorable safety profile for patients with concurrent tachyarrhythmias or myocardial ischemia.

Labetalol S.A.L.F. should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

The product is given by intravenous infusion. After reconstitution, the solution is administered via a controlled infusion pump, with the rate titrated to achieve the target blood pressure while monitoring heart rate, respiratory status, and signs of hypotension.

Serious adverse events include severe hypotension, bronchospasm in patients with reactive airway disease, heart block or profound bradycardia, hepatic injury, and rare anaphylactic reactions. Prompt recognition and immediate medical intervention are essential if any of these occur.

Labetalol is contraindicated in patients with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, uncompensated heart failure, severe asthma or chronic obstructive pulmonary disease, and in those with known hypersensitivity to the drug or its excipients.